Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.

There was a significant trend in the dose–response relationship between rivaroxaban and major bleeding ( P =0.039).

also in 6,185 other papers

Although the study was not powered to demonstrate significance in the composite efficacy endpoint of death, myocardial infarction, stroke or severe recurrent ischemia requiring revascularization, a definite trend towards reduction in cardiovascular events was also observed ( 47 ).

also in 240 other papers